Study shows BTG's Varisolve does not cause cerebral injury
This article was originally published in Scrip
Executive Summary
BTG's potential varicose vein therapy, Varisolve (polidocanol), does not to cause cerebral injury in patients with right-to-left cardiac shunts, according to the results of a US Phase II study presented at the American College of Phlebology's 22nd annual congress in Florida.